NCT07285811 GLycaemic Outcomes With Whey Protein in ageING
| NCT ID | NCT07285811 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Birmingham |
| Condition | Type 2 Diabetes |
| Study Type | INTERVENTIONAL |
| Enrollment | 32 participants |
| Start Date | 2026-01-02 |
| Primary Completion | 2027-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 32 participants in total. It began in 2026-01-02 with a primary completion date of 2027-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this placebo-controlled, partial crossover design study is to identify the impact of consuming whey protein before meals on free-living glucose control in older adults living with type 2 diabetes. The primary specific objective is to determine the effect of a thrice daily whey protein pre-meal supplementation at two doses, on glucose excursions over a 7-day free-living period in adults aged 70-90 years of age, living with type 2 diabetes, compared with a non-protein placebo. Participants will consume the whey protein and placebo for 7 days each, before each meal. All participants will consume the placebo and one of two doses of whey protein, in a randomised order.
Eligibility Criteria
* Male or female * 70-90 years old * Type 2 Diabetes (confirmed with glycated haemoglobin (HbA1c) \>6.5% in clinic or in SportExR) * Stable body mass (body mass index (BMI) ≤40kg/m2) * Generally healthy, assessed via a General Health Questionnaire (GHQ) * Some residual beta-cell activity (confirmed with urine test on induction) * Normal or moderately increased albuminuria (needs to be below 300mg/g) * Normal, mildly or moderately decreased glomerular filtration rate (GFR) (needs to be above 45ml/min/1.732). * Able and willing to attend SportExR a total of 5 times: 1 induction and 2 testing visits and 2 return check-up visits. Exclusion Criteria: * \<70 years old and over 90 years of age * Currently on fast-acting insulin therapy (i.e., Humalog) * Confirmed uncontrolled diabetes (HbA1C \>10% or 85mmol/mol). * Currently on GLP-1 therapy * Habitual smoker or vaper * Veganism * Lactose or dairy intolerance * Coeliac or gluten intolerance * History of gastrointestinal disease * Experienced a hyperglycaemic or hypoglycaemic event requiring treatment in the past 12 months * Recent Ischemic stroke (\<3 months). * Use of anticoagulants (e.g. warfarin, rivaroxaban) * Considered unwilling or unable to comply with the study protocol requirements by the research team
Contact & Investigator
Leigh Breen, PhD
PRINCIPAL INVESTIGATOR
University of Birmingham and University of Leciester
Frequently Asked Questions
Who can join the NCT07285811 clinical trial?
This trial is open to participants of all sexes, aged 70 Years or older, up to 90 Years, studying Type 2 Diabetes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07285811 currently recruiting?
Yes, NCT07285811 is actively recruiting participants. Contact the research team at l.breen@bham.ac.uk for enrollment information.
Where is the NCT07285811 trial being conducted?
This trial is being conducted at Birmingham, United Kingdom, Birmingham, United Kingdom.
Who is sponsoring the NCT07285811 clinical trial?
NCT07285811 is sponsored by University of Birmingham. The principal investigator is Leigh Breen, PhD at University of Birmingham and University of Leciester. The trial plans to enroll 32 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.